Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials

Area of Science:

• Oncology
• Drug Discovery
• Translational Medicine

Background:

• Current preclinical models for anticancer drug assessment exhibit low predictive value for clinical efficacy.
• A significant number of drug candidates demonstrating potent anticancer effects in preclinical settings ultimately fail in human trials.
• This discrepancy is often attributed to disease complexity and limitations of existing preclinical tools.

Purpose of the Study:

• To investigate the impact of preclinical design on the clinical success of anticancer drugs.
• To propose novel, patient-oriented in vitro and in vivo assays for evaluating anticancer drug candidates.
• To enhance the reliability of preclinical drug validation for improved clinical translation.

Main Methods:

• Development of two novel in vitro assays focused on patient-specific cancer characteristics.
• Design of two novel in vivo models incorporating patient-relevant disease parameters.
• Validation of proposed assays against existing preclinical methods and clinical outcomes.

Main Results:

• The proposed patient-oriented assays demonstrated a higher correlation with clinical drug response compared to traditional methods.
• Specific design elements in preclinical studies were identified as critical for predicting clinical efficacy.
• The novel assays provide a more accurate assessment of potential anticancer drug activity.

Conclusions:

• Suboptimal preclinical study design, neglecting patient needs, contributes to the high failure rate of anticancer drugs.
• Patient-centered in vitro and in vivo testing strategies can significantly improve the prediction of drug efficacy in cancer patients.
• Implementing these enhanced preclinical assessments can accelerate the development of effective cancer therapeutics.